BeiGene is investing US$700 million for the construction of its manufacturing, and R&D facility in New Jersey, USA.
The primary objective of this facility is to provide advanced capabilities for commercial-stage biologic pharmaceutical production, as well as support late-stage research and clinical development activities.
By establishing this facility, BeiGene aims to enhance its global capabilities and expand its presence in the United States.
The new site will feature approximately 400,000 square feet of dedicated space specifically designed for commercial-stage biologic pharmaceutical manufacturing. Moreover, there is potential for future expansion, with an additional 600,000 square feet to be incorporated over time.
This expansion will enable BeiGene to meet the increasing demand for its products and accommodate future growth opportunities.
Anticipated to be completed next year, the construction of the facility highlights BeiGene's commitment to swiftly establish a strong foothold in the United States.
By investing in cutting-edge infrastructure and resources, BeiGene aims to strengthen its research and development capabilities, accelerate the progress of its pipeline, and deliver innovative therapies to patients in need.